Low expression of stromal Gal1 detected by immunostaining in PDA tissue samples is associated to long-term survival [96], highlighting the potential of Gal1 expression as a biomarker for pancreatic cancer diagnosis and prognosis. This evidence concerns the gene LGALS1 and Patent ductus arteriosus.